Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia
- 1 September 1992
- journal article
- clinical trial
- Published by Elsevier in Atherosclerosis
- Vol. 96 (1), 53-64
- https://doi.org/10.1016/0021-9150(92)90037-h
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- HMG CoA reductase inhibitorsCurrent Opinion in Lipidology, 1991
- Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levelsJournal of Internal Medicine, 1990
- The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemiaEuropean Journal of Clinical Investigation, 1990
- Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemiaMetabolism, 1989
- Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemiaAtherosclerosis, 1989
- A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group IIIPublished by American Medical Association (AMA) ,1988
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1987
- Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.Journal of Clinical Investigation, 1984
- Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1984